Site News

Added 2 days ago Drug news

Phase III trial of Inflectra (infliximab CT-P13) meets endpoint in Crohn’s disease- Pfizer and Celltrion Healthcare

Data announced by Pfizer and Celltrion Healthcare showed that for patients with moderate-to-severe Crohn’s disease (CD), treatment with Inflectra (infliximab...

Added 2 days ago Drug news

Tivantinib fails to meet endpoint in METIV-HCC Phase III trial for hepatocellular carcinoma.- ArQule Inc. + Daiichi Sankyo

ArQule, Inc.and Daiichi Sankyo announced that the METIV-HCC phase III study of tivantinib in hepatocellular carcinoma (HCC) did not meet...

Added 3 days ago Drug news

Phase III ADMIRE-CD clinical trial of Cx 601 (adipose-derived stem cells) shows long term remission in Crohn's disease- Takeda/TiGenix

Takeda Pharmaceutical Company and TiGenix announced new data from the Phase III ADMIRE-CD clinical trial, which indicated that Cx 601,...

Added 3 days ago Drug news

METIV-HCC phase III study of ARQ 197 (tivantinib) in hepatocellular carcinoma fails to meet endpoint- ArQule and Daiichi Sankyo

ArQule and Daiichi Sankyo announced that the METIV-HCC phase III study of ARQ 197 (tivantinib) in hepatocellular carcinoma (HCC) did...

Added 3 days ago Drug news

GEMINI long-term safety study of Entyvio (vedolizumab) shows benefits in ulcerative colitis and Crohn's disease- Takeda

Takeda Pharmaceutical announced interim findings from the ongoing, open-label GEMINI long-term safety (LTS) study of Entyvio (vedolizumab). Data presented from...

Added 3 days ago Drug news

Long-term extension study of Stelara (ustekinumab) in adults with Crohn's disease shows response maintained for up to 2 years- Janssen Biotech

Janssen Biotech announced new two-year data from the ongoing IM-UNITI long-term extension (LTE) study evaluating the efficacy and safety of...

Added 3 days ago Drug news

Successful Phase III OLYMPIAD trial for Lynparza (olaparib) as a treatment of BRCA-mutated metastatic breast cancer . - Astra Zeneca

AstraZeneca announced positive results from its Phase III OLYMPIAD trial comparing Lynparza (olaparib) tablets (300mg twice daily) to physician’s choice...

Added 3 days ago Drug news

FDA accepts Mylan's BLA for MYL-1401H, a proposed biosimilar to Neulasta (pegfilgrastim).- Mylan + Biocon Ltd

Mylan N.V. and Biocon Ltd. announced that the FDA has accepted Mylan's Biologics License Application (BLA) for MYL-1401H, a proposed...

Added 4 days ago Industry news

Kalytera Therapeutics acquires Talent Biotechs and its programme for cannabidiol pharmaceuticals,

Kalytera Therapeutics, Inc. announced that it has successfully completed the previously announced acquisition of Talent Biotechs Ltd., strengthening Kalytera’s position...

Added 4 days ago Drug news

NICE rejects Venclexta (venetoclax) as a treatment for chronic lymphocytic leukemia.- AbbVie + Roche

The National Institution for Health and Care Excellence (NICE) has in its first draft guidance rejected Venclexta (venetoclax) from AbbVie...

View all news articles